Genzyme re-ups and beefs up business with Hospira for fill/finish ops

Genzyme will have Hospira conduct the final steps of manufacturing for a growing list of drugs under a new supply agreement. Hospira will provide fill/finish services for Cerezyme, Fabrazyme, Thyrogen and Myozyme, as it has been according to a previous agreement, as well as Lumizyme, Thymoglobulin, Campath and products in development. Article

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.